Alex Michael Azar II (; born June 17, 1967) is an American attorney, businessman, lobbyist, and former pharmaceutical executive who served as the 24th U.S. secretary of health and human services from 2018 to 2021. He was also chairman of the White House Coronavirus Task Force from its inception in January 29, 2020 to February 26, 2020, when he was replaced by Vice President Mike Pence.
In 2021, he was appointed a senior executive in residence at the Miami Herbert Business School at the University of Miami.
From 2012 to 2017, Azar was president of the U.S. division of Eli Lilly and Company, a major drug company, and a member of the board of directors of the Biotechnology Innovation Organization, a large pharmaceutical trade association.
Azar served as general counsel of the U.S. Department of Health and Human Resources (HHS) from 2001 to 2005. On July 22, 2005, he was confirmed as the deputy secretary of health and human services; he served in that capacity until his January 2007 resignation.
Early life and education Azar was born on June 17, 1967, in Johnstown, Pennsylvania, the son of Lynda (Zarisky) and Alex Michael Azar Sr. His father is a retired ophthalmologist who practiced ophthalmology in Salisbury, Maryland, for more than 30 years, and taught at Johns Hopkins Hospital. His grandfather emigrated from Lebanon in the early 20th century. The family originates from Amioun.
Azar attended Parkside High School in Salisbury, Maryland, where he graduated in 1985. He received a B.A. degree summa cum laude in government and economics from Dartmouth College in 1988. He belonged to the Kappa Kappa Kappa fraternity. He earned a J.D. degree from Yale Law School in 1991, where he served as a member of the executive committee of the Yale Law Journal.
Career Law career
After law school, from 1991 to 1992, Azar served as a law clerk for Judge Alex Kozinski of the United States Court of Appeals for the Ninth Circuit. Azar left after six weeks, and was replaced in Kozinski's chambers by Brett Kavanaugh. Azar subsequently clerked for the remainder of the term for Judge J. Michael Luttig of the United States Court of Appeals for the Fourth Circuit. From 1992 to 1993, he served as a law clerk for Associate Justice Antonin Scalia of the United States Supreme Court.
From 1994 to 1996, he served as an associate independent counsel for Ken Starr in the United States Office of the Independent Counsel, where he worked on the first two years of the investigation into the Whitewater controversy. At the time of Azar's appointment, he was working as an associate in Starr's law firm.
Between 1996 and 2001, Azar worked for Wiley Rein, a Washington, D.C., law firm, where he achieved partner status.
Health and Human Services
On August 3, 2001, Azar was confirmed as general counsel of the United States Department of Health and Human Services. George W. Bush's first HHS secretary, Tommy Thompson, said Azar played an important role in responding to the 2001 anthrax attacks, ensuring there was a vaccine ready for smallpox, and dealing with outbreaks of SARS and influenza. On July 22, 2005, Azar was confirmed as the deputy secretary of Health and Human Services. He was twice confirmed unanimously by the United States Senate.
Working under Secretary Mike Leavitt, Deputy Azar supervised the operation of HHS, which would grow to an annual budget of over $1 trillion by 2017 when he was appointed secretary. Azar led the development and approval of HHS regulations, led U.S. government efforts to encourage worldwide pharmaceutical and medical device innovation, and was in charge of the HHS response to an initiative implemented by President George W. Bush to improve government performance. Azar resigned in January 2007.
Eli Lilly and Company In June 2007, Azar was hired by Eli Lilly and Company chief executive officer Sidney Taurel to be the company's top lobbyist and spokesman as its senior vice president of corporate affairs and communications.
In April 2009, Azar became vice president of Lilly's U.S. Managed Healthcare Services organization and its Puerto Rico affiliate. In 2009, the company paid $1.415 billion to settle criminal charges regarding its promotion of antipsychotic drug Zyprexa (olanzapine) for off-label uses between 1999 and 2005.
Effective January 1, 2012, Azar became president of Lilly USA, LLC, the largest division of Eli Lilly and Company, and was responsible for the company's entire operations in the United States. Prices for drugs rose substantially under Azar's leadership, including the tripling of the cost of the company's top-selling insulin drug. Also under Azar's watch, Eli Lilly was one of three companies accused in a class-action lawsuit of exploiting the drug pricing system to increase profits for insulin. Eli Lilly was also fined in Mexico for colluding on the price of insulin.
In connection with the position, Azar served on the board of directors of the Biotechnology Innovation Organization, a pharmaceutical lobby.
In January 2017, Azar resigned from Eli Lilly "to pursue other career opportunities" as a result of a company reorganization. He also resigned from the board of directors of the Biotechnology Innovation Organization. In his last year at the corporation he earned $2 million.Cronyism and Conflicts of Interest In Trump's Coronavirus Task Force , The Intercept, Sharon Lerner, February 29, 2020. Retrieved March 12, 2020.
U.S. Secretary of Health and Human Services (2018–2021) Nomination and confirmation
On November 13, 2017, President Trump announced via Twitter that he would nominate Azar to be the next secretary of health and human services.
Many health care advocates raised concerns about the nomination, citing Azar's track record of raising drug prices and his opposition to Obamacare.Advocacy Groups Slam Azar Ahead of Committee Hearing , HEALTHCAREDIVE, David Lim, January 4, 2018. Retrieved February 28, 2020. Critics noted that Azar approved a tripling of the price of insulin while vice president of Managed Healthcare Services of Eli Lilly.HHS Secretary Alex Azar now wants the Trump administration to import cheaper drugs from Canada , Newsweek, Alexandra Hutzler, July 31, 2019. Retrieved February 28, 2020. Speaking in favor of his nomination were two former U.S. Senate majority leaders, Democrat Tom Daschle and Republican Bill Frist. Both those endorsers were affiliated with the Bipartisan Policy Center, a Washington, D.C., think-tank which receives support from Eli Lilly."Pundits Funded by Drug Company Applaud Its Takeover of Trump Health Department" , The Intercept, Zaid Jilani, November 29, 2017. Retrieved March 12, 2020.
In spite of objections, his nomination was relatively smooth. Azar was confirmed on January 24, 2018, with a 55–43 vote. with most Democrats opposed. Voting against him, Oregon senator Ron Wyden, ranking member on the Senate Finance Committee, said that while Azar was at Eli Lilly, he "never, not one time, signed off on a decrease in the price of a drug.""Meet HHS Secretary Alex Azar, the Official Chairing the Coronavirus Task Force" , Time, Tessa Berenson, February 27, 2020. Retrieved February 28, 2020. Senator Bernie Sanders said in a press release, "The nomination of Alex Azar, the former head of Eli Lilly's U.S. operations, shows that Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'." "The last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services." During that tenure, Eli Lilly was fined for colluding to maintain high drug costs in Mexico.What You Need to Know about Alex Azar, Trump's HHS Nominee , Scientific American, Dina Fine Maron, November 28, 2017. Retrieved March 10, 2020.
Azar had additionally consulted with numerous other biopharmaceutical and health insurance corporations regarding government policy, product access, sales and marketing, pricing, reimbursement, and distribution. He was confirmed by the Senate on January 24, 2018, and sworn in by Vice President Pence on January 29, 2018.
From March to December 2018, Azar sat on the Federal Commission on School Safety.
Azar had prolonged disputes with Seema Verma, who was Trump's administrator of the Centers for Medicare & Medicaid Services (CMS). She accused Azar and his HHS predecessor, Tom Price, of sexist management; an inquiry by a former Trump HHS official, Heather Flick, concluded that Azar had not discriminated. Azar was widely reported to spar with his subordinates, leading to criticism of his handling of the COVID-19 pandemic response.
On January 20, 2021, immediately after the end of the Trump administration, China sanctioned Azar and other Trump administration officials. The sanctioned people cannot travel to China and cannot do business with China. President Biden's National Security Council called the sanctions "unproductive and cynical."
Healthcare policy Security Strategy As Secretary of Health, Azar presided over the release of the Trump administration's National Biodefense Strategy in 2018 and the Global Health Security Strategy in 2019.
Affordable Care Act Azar was an opponent of the Affordable Care Act, also known as Obamacare. and predicted in 2017, "There will be a piece of legislation passes this year that is called the repeal of Obamacare. I don't know what's going to be in the substance of it, but there will be a piece of legislation that says that." Also regarding the ACA, Azar said the Department of Health and Human Services has latitude to "make it work a little better".
Abortion Azar opposes abortion. In a written response to Senator Patty Murray regarding future HHS policy, he said, "The mission of HHS is to enhance the health and well-being of all Americans, and this includes the unborn."
Regulations
According to The New York Times, Azar differed with his predecessor, Tom Price, in his approach to regulations. Writing in May 2018, the Times reported, "in a sharp break from his predecessor – and from most Trump cabinet secretaries – he seems to be relishing the chance to write new regulations, rather than just crossing out Obama-era ones."
COVID-19 Outbreak
Azar learned about the COVID-19 threat on January 3, 2020. Azar informed associates that he had alerted Trump on January 18, 2020, regarding the potential danger from COVID-19, but that the president thought he was being "alarmist" as Azar struggled to get Trump's attention to focus on the issue.The Worst President. Ever. , The Washington Post, Max Boot, April 5, 2020. Retrieved April 6, 2020. Despite Azar's warnings, four days later, Trump announced, "We have it totally under control. It's one person coming in from China." On January 28, 2020, Azar stated that the Trump administration had no plan to declare a public health emergency as the COVID-19 virus spread in China. He asserted that the risk to Americans was minimal, but admitted that authorities in 30 states were monitoring potential cases and added that he would not "hesitate at all to invoke any authorities I need to, to ensure we're taking all steps to protect the American people, but I'll do it when it's appropriate." U.S. senator Rick Scott, U.S. representative Vern Buchanan, and other Republicans demanded that a public health emergency be declared as a means of budgeting necessary federal funding to deal with the potential pandemic.